A combination of Celgene Corp.'s cancer drug Revlimid and dexamethasone proved safe and effective in extending the lives of multiple myeloma patients, researchers report. Their study found a 93% survival rate for those on the combination therapy, compared to 91% of patients who received dexamethasone alone. The trial design underplayed differences between the two groups because if a patient in the dexamethasone-only group relapsed, the patient was then given Revlimid.

Full Story:

Related Summaries